Overview

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This was a long-term safety study HPN-100 in urea cycle disorder (UCD) subjects. Subjects were assessed regularly for safety and control of their venous ammonia. Hyperammonemic events were characterized with respect to contributing factors, such as intercurrent illness, diet, and noncompliance with medication.
Phase:
Phase 3
Details
Lead Sponsor:
Horizon Pharma Ireland, Ltd., Dublin Ireland
Treatments:
4-phenylbutyric acid
Glycerol